Newsletter | June 27, 2019

06.27.19 -- Physicians Speak Out On Biosimilar Value

 
Featured Editorial
Physicians Speak Out About Biosimilar Value
 
By Anna Rose Welch, editor, Biosimilar Development

Though savings and access are two of the biggest goals and perks of biosimilars, several physicians at a recent conference argued there is another critical benefit of greater biosimilar use.

Can The FTC Clear A Path For Biosimilar Access Through The Patent Thicket?
 
By Stanton R. Mehr, Biosimilars Review & Report

In recent months there have been congressional hearings examining alleged anticompetitive patenting practices currently barring biosimilar competition. One potential action that could be taken is to allow the FTC to clear certain market access barriers that are halting biosimilar competition, including the patent thickets protecting market exclusivity after the originator's central composition-of-matter patent has expired.

Industry Insights
A 19-Color Multiparameter White Blood Cell Panel Designed For The Immunophenotyping Of Normal And Malignant Leukocytes By Flow Cytometry
Article | By Michelle Scott, Chris Brampton, Ph.D., and Kelly Kroeger, Ph.D., Bio-Rad Laboratories, Inc.

Flow cytometry is an important tool for the diagnosis and classification of leukemia. While many leukocyte markers have been identified, and are used to determine the exact subtypes of leukemia a patient may have, high-dimensional multicolor analysis has been limited by instrument capabilities. This has often resulted in splitting a valuable limited sample into multiple independent tests to fully define the patient’s phenotype.

Converting From ELISA To Biacore SPR Assays
Application Note | GE Healthcare Life Sciences

Biacore SPR assays provide an automated and reproducible real-time determination of active concentrations that can be considered an alternative to a traditional ELISA approach. This article provides general guidance on how to convert an existing ELISA assay to a Biacore SPR-assay and, by doing so, shows how you can get results in less than half the time compared with ELISA.

Connect With Biosimilar Development:
      Twitter